Managing CLL With BTK Inhibitors

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Management of Treatment-Naive CLL

Alliance A041202 Phase 3 Trial of Ibrutinib Alone or With Rituximab

Alliance A041202 Results

iLLUMINATE Trial Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab

ECOG-ACRIN E1912 Trial Ibrutinib + Rituximab vs FCR

ECOG-ACRIN E1912 Trial Results

ECOG-ACRIN E1912 Trial Results (cont)

Deciding When to Use Ibrutinib

Discussion Use of Ibrutinib

CLL14 Trial Venetoclax and Obinutuzumab

Predictors of Poor Response to Ibrutinib

informCLLTM Real-World Registry Prognostic Testing and Treatment Approaches in CLL

Acalabrutinib A Selective BTK Inhibitor

Acalabrutinib in Ibrutinib-Intolerant Patients

Next-Generation BTK Inhibitors

ACE-CL-001 Study Acalabrutinib in Treatment-Naive CLL/SLL

ACE-CL-001 Study Response Rates

Development of Ibrutinib Resistance in CLL

CAPTIVATE Trial Ibrutinib + Venetoclax in Treatment-Naive CLL/SLL

Using BTK Inhibitors in Clinical Practice

Some Ibrutinib-Associated Toxicities May Emerge After Longer-Term Use

Management Tips Hypertension, Atrial Fibrillation, and Bleeding

Toxicities Associated With Acalabrutinib

Dose Reductions

Managing Hypertension

Concluding Remarks

Abbreviations

Abbreviations